Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446885 | 0.89 | NOTUM (1.00) | NOTUMKDM4EALDH1A1AMPD2HDAC1 | |
| SCHEMBL17446887 | 0.86 | NOTUM (1.00) | NOTUMKDM4EALDH1A1AMPD2HDAC1 | |
| SCHEMBL655024 | 0.82 | NOTUM (0.80) | NOTUMKDM4EALDH1A1AMPD2HDAC1 | |
| SCHEMBL9910961 | 0.82 | NOTUM (0.80) | NOTUMKDM4EALDH1A1AMPD2HDAC1 | |
| SCHEMBL12153230 | 0.81 | NOTUM (0.78) | NOTUMKDM4EALDH1A1AMPD2HDAC1 | |
| Hydrochloric Acid SCHEMBL2257588 | 0.81 | NOTUM (0.78) | NOTUMKDM4EALDH1A1AMPD2HDAC1 | |
| SCHEMBL1614374 | 0.81 | NOTUM (0.52) | NOTUMHSD17B3 | |
| SCHEMBL1223510 | 0.80 | NOTUM (0.76) | NOTUMHDAC1HDAC6 | |
| SCHEMBL17538386 | 0.79 | NOTUM (0.74) | NOTUMKDM4EALDH1A1AMPD2HDAC1 | |
| SCHEMBL13676986 | 0.79 | NOTUM (0.74) | NOTUMKDM4EALDH1A1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | NOTUM 4008/4885KDM4E 1436/4885ALDH1A1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.